In Vivo Viral-based CAR-T Cell Engineering Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Prospect of In Vivo Viral-based CAR-T Cell Engineering

Traditional ex vivo CAR-T cells are personalized cell therapy products, which require expensive and time-consuming manufacturing processes and it's easy to cause adverse symptoms such as cytokine release syndrome (CRS). It is extremely important to investigate novel techniques to overcome these obstacles. In vivo viral-based CAR-T cell programming allows direct generation of CAR-T cells in situ. This approach simplifies the operation and avoids the process of engineering T cells in vitro, and reduces possible complications such as CRS.

Fig.1 Diverse vectors used for in vivo CAR-T cells therapy. (Michels, et al., 2022)

Our In Vivo Viral-based CAR-T Cell Engineering Service

Powered by years of experience in CAR-T research, Creative Biolabs has successfully established an in vivo viral-based CAR-T cell engineering service platform to assist our global customers. Our in vivo viral-based CAR-T cell engineering service utilizes integrated viral vectors such as lentiviral (LV) vectors and adenovirus-associated vectors (AAV) to generate CAR-T cells in situ. We support global customers' requirements with all-around comprehensive customized service including but not limited to CAR design, vector construction & modification, in vivo CAR-T programming on animal models, and CAR-T function validation.

Fig.2 In vivo generation of CAR-T Cells. (Agarwal, et al., 2020)

Our Capability

Representative Data

Representative Data1: Several effective in vivo CAR-T cell production with optimization in vector design poses a breakthrough in cancer immunotherapy.

Representative Data Table 1: Preclinical data providing evidence for in vivo CAR-T cell generation (Michels, et al., 2022)

Representative Data2: A lentiviral-based platform for in vivo CAR T-cell engineering, VivoVec, showed anti-tumor efficacy in both hematological and solid cancers.

Fig.3: UB-VV100 activates and transduces unstimulated T cells. (Michels, et al., 2023)

In the field of in vivo CAR-T engineering, we are committed to developing novel approaches to greatly enhance its effectiveness in cancer therapy. At the same time, we also provide the following related services:

For more details about our in vivo viral-based CAR-T cell engineering service, please don't hesitate to contact us, our seasoned experts will be pleased with your order.

References

Michels, A.; et al. Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol Ther. 2022, 30(7): 2401-2415.
Agarwal, S.; et al. In vivo generation of CAR-T cells selectively in human CD4+ lymphocytes. Mol Ther. 2020, 28(8): 1783-1794.
Michels, K.R.; et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023, 11(3): e006292.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION